Shots:

• Biogen’s decision of acquisition of TMS-007 based on the safety- imaging- and clinical outcome data from the P-IIa study which showed positive impacts on both blood vessel reopening in the brain- as well as patient functional recovery with no incidence of sICH
• TMS to receive $18M upon acquisition of TMS-007 and is eligible to receive up to $335M as post-acquisition payment upon the achievement of certain milestones along with royalties on annual WW net sales
• Biogen will be responsible for the development- manufacturing- and commercialization of TMS-007- following the acquisition and is currently assessing the next steps for the clinical development of TMS-007

  Ref: GLOBE NEWSWIRE | Image: Biogen